# IMMUNISBIO Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunisbio-co

- Industry: Biotechnology
- Headquarters: Incheon, South Korea
- Website: www.immunisbio.com
- Total disclosed funding: $4M
- Latest round: Series B (Feb 1, 2021)
- Investors on record: 3

## About

Based in Incheon, South Korea, and founded in 2016, IMMUNISBIO Co., Ltd. operates as a cell therapy development company that is focused on the development of immune cell therapy such as immune cell therapy, functional cosmetics, culture automation, and technology export, with the goal of curing cancer-related diseases. In February 2021, IMMUNISBIO Co., Ltd. raised KRW 4.5 billion in series B funding led by new investor Samho Green Investment.  New investors Sejong Venture Partners and Honest Ventures also participated in this round.

## Funding rounds

- Series B, Feb 1, 2021, $4M — Samho Green Investment, Sejong Venture Partners, Honest Ventures

## Investors

- Samho Green Investment (https://capitalatlas.ai/funds/samho-green-investment) — Series B
- Sejong Venture Partners — Series B
- Honest Ventures (https://capitalatlas.ai/funds/honest-ventures) — Series B